If you purchase this report now and we update it in new 100 days, get it free!
List of Tables:
Table 1. Snapshot of Switzerland Clinical Trials Market in Balanced Perspective, 2022-2031 18
Table 2. Total Number of Registered Clinical Studies Worldwide, 2010-2021 22
Table 3. World Economic Outlook, 2021-2031 24
Table 4. World Economic Outlook, 2021-2023 25
Table 5. Scenarios for Economic Impact of Ukraine Crisis 29
Table 6. World Health Spending by Region, $ bn, 2013-2020 38
Table 7. Main Product Trends and Market Opportunities in Switzerland Clinical Trials Market 42
Table 8. Switzerland Clinical Trials Market by Product Category, 2021-2031, $ mn 50
Table 9. Switzerland Clinical Trials Market: Trials of Drugs by Drug Type, 2021-2031, $ mn 52
Table 10. Switzerland Clinical Trials Market by Phase, 2021-2031, $ mn 59
Table 11. Switzerland Clinical Trials Market by Design, 2021-2031, $ mn 65
Table 12. Switzerland Clinical Trials Market: Interventional Studies by Segment, 2021-2031, $ mn 68
Table 13. Switzerland Clinical Trials Market: Observational Studies by Segment, 2021-2031, $ mn 73
Table 14. Switzerland Clinical Trials Market by Service Type, 2021-2031, $ mn 79
Table 15. Switzerland Clinical Trials Market by Indication, 2021-2031, $ mn 91
Table 16. Number of Oncology Clinical Trials and Number of Patients in Switzerland by Cancer Type, as of March 2023 94
Table 17. Switzerland Clinical Trials Market by End User, 2021-2031, $ mn 103
Table 18. Switzerland Clinical Trials Market by Region, 2021-2031, % of Revenue 109
Table 19. Switzerland Clinical Trials Market by Region, 2021-2031, $ mn 110
Table 20. Accell Clinical Research LLC: Company Snapshot 115
Table 21. Accell Clinical Research LLC: Business Segmentation 116
Table 22. Accell Clinical Research LLC: Product Portfolio 116
Table 23. Charles River Laboratories: Company Snapshot 117
Table 24. Charles River Laboratories: Product Portfolio 118
Table 25. Charles River Laboratories: Breakdown of Revenue by Division 118
Table 26. Charles River Laboratories: Breakdown of Revenue by Region 119
Table 27. ClinDatrix Inc: Company Snapshot 120
Table 28. Clinipace: Company Snapshot 121
Table 29. Clinipace: Product Portfolio 122
Table 30. Eli Lilly and Company: Company Snapshot 123
Table 31. Eli Lilly and Company: Pharmaceutical Brands 124
Table 32. Eli Lilly and Company: Clinical Trial Service 124
Table 33. Eli Lilly and Company: Breakdown of Revenue by Therapeutic Area 124
Table 34. Eli Lilly and Company: Breakdown of Revenue by Region 125
Table 35. F. Hoffmann-La Roche: Company Snapshot 126
Table 36. F. Hoffmann-La Roche: Clinical Trial Service 126
Table 37. F. Hoffmann-La Roche: Business Segmentation 127
Table 38. F. Hoffmann-La Roche: Revenue by Region 127
Table 39. ICON Plc: Company Snapshot 129
Table 40. ICON Plc: Business Segmentation 129
Table 41. ICON Plc: Product Portfolio 130
Table 42. ICON Plc: Revenue by Region, 2020, % 130
Table 43. IQVIA Holdings Inc.: Company Snapshot 132
Table 44. IQVIA Holdings Inc.: Business Segmentation 133
Table 45. IQVIA Holdings Inc.: Revenue by Region, 2020, % 133
Table 46. IQVIA Holdings Inc.: Product Portfolio 134
Table 47. Covance Inc.: Company Snapshot 136
Table 48. Covance Inc.: Product Portfolio 137
Table 49. Covance Inc.: Revenue by Region, 2020, % 138
Table 50. Novo Nordisk: Company Snapshot 140
Table 51. Novo Nordisk: Product Portfolio 141
Table 52. Novo Nordisk: Breakdown of Revenue by Business Segment 142
Table 53. Novo Nordisk: Breakdown of Revenue by Region 142
Table 54. PAREXEL International Corporation: Company Snapshot 143
Table 55. PAREXEL International Corporation: Business Segmentation 144
Table 56. PAREXEL International Corporation: Revenue by Region, 2018, % 144
Table 57. PAREXEL International Corporation: Product Portfolio 145
Table 58. Pfizer Inc.: Company Snapshot 147
Table 59. Pfizer Inc.: Business Segmentation 148
Table 60. Pfizer Inc.: Breakdown of Revenue by Product Category 148
Table 61. Pfizer Inc.: Breakdown of Revenue by Region 149
Table 62. Pfizer Inc.: Product Portfolio 149
Table 63. Pfizer Inc.: Revenue, 2018-2020, $ bn 150
Table 64. Pharmaceutical Product Development LLC (PPD): Company Snapshot 152
Table 65. Pharmaceutical Product Development LLC (PPD): Breakdown of Revenue by Division 153
Table 66. Pharmaceutical Product Development LLC (PPD): Breakdown of Revenue by Region 153
Table 67. Phlexglobal: Company Snapshot 155
Table 68. PRA Health Sciences Inc.: Company Snapshot 157
Table 69. PRA Health Sciences Inc.: Business Segmentation 158
Table 70. PRA Health Sciences Inc.: Revenue by Region, 2018, % 158
Table 71. Sanofi: Company Snapshot 159
Table 72. Sanofi: Business Segmentation 160
Table 73. Sanofi: Breakdown of Revenue by Region 160
Table 74. SGS SA (SGS Life Sciences): Company Snapshot 162
Table 75. SGS SA (SGS Life Sciences): Business Segmentation 163
Table 76. SGS SA (SGS Life Sciences): Revenue by Region, 2018, % 163
Table 77. Syneos Health Inc.: Company Snapshot 165
Table 78. Syneos Health Inc.: Business Segmentation 166
Table 79. Syneos Health Inc.: Revenue by Region, 2020, % 166
Table 80. WuXi AppTec Inc.: Company Snapshot 168
List of Figures:
Figure 1. Research Method Flow Chart 12
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 3. Switzerland Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2031 17
Figure 4. Switzerland Clinical Trials Market, 2021-2031, $ mn 21
Figure 5. Impact of COVID-19 on Business 26
Figure 6. Primary Drivers and Impact Factors of Switzerland Clinical Trials Market 32
Figure 7. Percentage of Trial Participants by Country, 2015-2019 35
Figure 8. Leading Causes of Death in the World, 2000 and 2019, million 36
Figure 9. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 37
Figure 10. World Population 65 and Over, % of Total Population, 1950-2060 37
Figure 11. Primary Restraints and Impact Factors of Switzerland Clinical Trials Market 39
Figure 12. Investment Opportunity Analysis 43
Figure 13. Porter’s Fiver Forces Analysis of Switzerland Clinical Trials Market 46
Figure 14. Breakdown of Switzerland Clinical Trials Market by Product Category, 2021-2031, % of Revenue 51
Figure 15. Switzerland Addressable Market Cap in 2023-2031 by Product Category, Value ($ mn) and Share (%) 51
Figure 16. Switzerland Clinical Trials Market by Product Category: Trials of Drugs, 2021-2031, $ mn 52
Figure 17. Switzerland Clinical Trials Market by Trials of Drugs: Small Molecule Drugs, 2021-2031, $ mn 53
Figure 18. Switzerland Clinical Trials Market by Trials of Drugs: Vaccines, 2021-2031, $ mn 54
Figure 19. Switzerland Clinical Trials Market by Trials of Drugs: Cell & Gene Therapy, 2021-2031, $ mn 55
Figure 20. Switzerland Clinical Trials Market by Trials of Drugs: Other Drugs, 2021-2031, $ mn 56
Figure 21. Switzerland Clinical Trials Market by Product Category: Trials of Devices, 2021-2031, $ mn 57
Figure 22. Switzerland Clinical Trials Market by Product Category: Trials of Procedures, 2021-2031, $ mn 58
Figure 23. Breakdown of Switzerland Clinical Trials Market by Phase, 2021-2031, % of Sales Revenue 60
Figure 24. Switzerland Addressable Market Cap in 2023-2031 by Phase, Value ($ mn) and Share (%) 60
Figure 25. Switzerland Clinical Trials Market by Phase: Phase I, 2021-2031, $ mn 61
Figure 26. Switzerland Clinical Trials Market by Phase: Phase II, 2021-2031, $ mn 62
Figure 27. Switzerland Clinical Trials Market by Phase: Phase III, 2021-2031, $ mn 63
Figure 28. Switzerland Clinical Trials Market by Phase: Phase IV, 2021-2031, $ mn 64
Figure 29. Breakdown of Switzerland Clinical Trials Market by Design, 2021-2031, % of Sales Revenue 66
Figure 30. Switzerland Addressable Market Cap in 2023-2031 by Design, Value ($ mn) and Share (%) 66
Figure 31. Switzerland Clinical Trials Market by Design: Interventional Studies, 2021-2031, $ mn 67
Figure 32. Switzerland Clinical Trials Market by Interventional Studies: Randomized Control Trial, 2021-2031, $ mn 69
Figure 33. Switzerland Clinical Trials Market by Interventional Studies: Adaptive Clinical Trial, 2021-2031, $ mn 70
Figure 34. Switzerland Clinical Trials Market by Interventional Studies: Non-randomized Control Trial, 2021-2031, $ mn 71
Figure 35. Switzerland Clinical Trials Market by Design: Observational Studies, 2021-2031, $ mn 72
Figure 36. Switzerland Clinical Trials Market by Observational Studies: Cohort Study, 2021-2031, $ mn 74
Figure 37. Switzerland Clinical Trials Market by Observational Studies: Case Control Study, 2021-2031, $ mn 75
Figure 38. Switzerland Clinical Trials Market by Observational Studies: Cross Sectional Study, 2021-2031, $ mn 76
Figure 39. Switzerland Clinical Trials Market by Observational Studies: Ecological Study, 2021-2031, $ mn 77
Figure 40. Switzerland Clinical Trials Market by Design: Expanded Access Trials, 2021-2031, $ mn 78
Figure 41. Breakdown of Switzerland Clinical Trials Market by Service Type, 2021-2031, % of Revenue 80
Figure 42. Switzerland Addressable Market Cap in 2023-2031 by Service Type, Value ($ mn) and Share (%) 80
Figure 43. Switzerland Clinical Trials Market by Service Type: Protocol Designing, 2021-2031, $ mn 81
Figure 44. Switzerland Clinical Trials Market by Service Type: Site Identification, 2021-2031, $ mn 82
Figure 45. Switzerland Clinical Trials Market by Service Type: Patient Recruitment, 2021-2031, $ mn 83
Figure 46. Switzerland Clinical Trials Market by Service Type: Laboratory Services, 2021-2031, $ mn 84
Figure 47. Switzerland Clinical Trials Market by Service Type: Bioanalytical Testing Services, 2021-2031, $ mn 85
Figure 48. Switzerland Clinical Trials Market by Service Type: Clinical Trial Data Management Services, 2021-2031, $ mn 86
Figure 49. Switzerland Clinical Trials Market by Service Type: Clinical Trial Supply & Logistic Services, 2021-2031, $ mn 87
Figure 50. Switzerland Clinical Trials Market by Service Type: Decentralized Clinical Trial Services, 2021-2031, $ mn 88
Figure 51. Switzerland Clinical Trials Market by Service Type: Medical Device Testing Services, 2021-2031, $ mn 89
Figure 52. Switzerland Clinical Trials Market by Service Type: Other Clinical Trial Services, 2021-2031, $ mn 90
Figure 53. Breakdown of Switzerland Clinical Trials Market by Indication, 2021-2031, % of Revenue 92
Figure 54. Switzerland Addressable Market Cap in 2023-2031 by Indication, Value ($ mn) and Share (%) 92
Figure 55. Switzerland Clinical Trials Market by Indication: Oncology, 2021-2031, $ mn 93
Figure 56. Switzerland Clinical Trials Market by Indication: Infectious Diseases, 2021-2031, $ mn 95
Figure 57. Switzerland Clinical Trials Market by Indication: Cardiology, 2021-2031, $ mn 96
Figure 58. Switzerland Clinical Trials Market by Indication: Obesity, 2021-2031, $ mn 97
Figure 59. Switzerland Clinical Trials Market by Indication: Diabetes, 2021-2031, $ mn 98
Figure 60. Switzerland Clinical Trials Market by Indication: Neurology, 2021-2031, $ mn 99
Figure 61. Switzerland Clinical Trials Market by Indication: Immunology, 2021-2031, $ mn 100
Figure 62. Switzerland Clinical Trials Market by Indication: Pain Management, 2021-2031, $ mn 101
Figure 63. Switzerland Clinical Trials Market by Indication: Other Indications, 2021-2031, $ mn 102
Figure 64. Breakdown of Switzerland Clinical Trials Market by End User, 2021-2031, % of Revenue 103
Figure 65. Switzerland Addressable Market Cap in 2023-2031 by End User, Value ($ mn) and Share (%) 104
Figure 66. Switzerland Clinical Trials Market by End User: Pharmaceutical and Biotechnological Companies, 2021-2031, $ mn 105
Figure 67. Switzerland Clinical Trials Market by End User: Clinical Research Organizations, 2021-2031, $ mn 106
Figure 68. Switzerland Clinical Trials Market by End User: Clinical Testing Laboratories, 2021-2031, $ mn 107
Figure 69. Switzerland Clinical Trials Market by End User: Other End Users, 2021-2031, $ mn 108
Figure 70. Growth Stage of Switzerland Clinical Trials Industry over the Forecast Period 111
Safe and Secure SSl Encryption
Licensing options
2600
USD
You can select one of these options upon checking out
Allows one individual to access the purchased report
Allows up to five individuals to access the purchased report
Allows all employees of an organization to access the purchased report. Internal sharing only
Allows all employees of an organization to access the purchased report. It also permits the use of up to 4 paragraphs or 1 page of the report externally in whitepapers, press releases, and marketing collateral
Use WELCOME to avail 10 % discount
North America: +1 201 793 8545 Europe: +44 20 8089 0049 Asia-Pacific: +91 7878231309
Email us on:- sales@bonafideresearch.com
Order Placed (04 October, 2023)
Notify To Team (04 October, 2023)
Report updation (05 October, 2023)
Report Quality Check (05 October, 2023)
Report Dispatch (06 October, 2023)
Hard Copy
Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.
We offer $1000 worth of FREE customization at the time of purchase
80% of the clinet request tailor made solution, how can we help you?
Avail customized purchase options to meet your exact research needs:
READY TO MIX MARKET HAS HELPED US TO UNDERSTAND PRODUCT, PRICE & VARIENTS OF ALL THE COMPETITION INCLUDING SMALL STARTUPS/REGIONAL PLAYERS.
CEO
Vivek Arora
BEING A STARTUP WE WERE NOT AWARE ABOUT E-COMMERCE LOGISTICS, THE REPORT HAS RESOLVED ALL OUR QUERIES. THE TEAM HAVE IN DEPTH KNOWLEDGE OF LOGISTICS. REMARKABLE!!
EXECUTIVE DIRECTOR
Rahul Roy
THE REPORT WAS GOOD FOR OUR STUDY, I WOULD STRONGLY RECOMMEND BONAFIDE RESEARCH. A VERY CUSTOMER CENTRIC AND APPROACHABLE TEAM.
SALES DIRECTOR
Arjun Prasad
THE COMPANY WHICH THOROUGHLY UNDERSTANDS INDIAN CONSUMER AND INDIAN MARKET. WE ARE REALLY HAPPY TO WORK WITH BONAFIDE RESEARCH
President
Manish Verma
Bonafide Research did an outstanding work on Global Hand Sanitizer project. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.
MARKETING DIRECTOR
Gautam Saxena
The study done by Bonafide Research was customized with all our needs. We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done.
PRODUCT MANAGER
Tom Stone
I’m glad I decided to work with you. Thankful to the team for the amazing coordination, it was indeed a good experience, would definitely recommend and come back for future prospects.
Associate Director
Mark Wood
Switzerland clinical trials market is projected to grow by 6.8% annually in the forecast period and reach $824.5 million by 2031, driven by the increasing number of clinical trials and increase in demand for novel therapies, rising prevalence on chronic diseases such as cancer and diabetes, the outbreak of tropical and infectious diseases such as COVID-19, and the increase in government initiatives and R&D investments. Highlighted with 80 tables and 70 figures, this 170-page report “Switzerland Clinical Trials Market 2022-2031 by Product Category (Drugs, Devices, Procedures), Phase (I, II, III, IV), Design (Interventional, Observational, Expanded Access), Service Type (Site Identification, Lab Services, Supply & Logistic, Decentralized Services), Indication (Oncology, Infectious Diseases, Cardiology, Obesity, Diabetes, Neurology), End User, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Switzerland clinical trials market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2022 and provides forecast from 2023 till 2031 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Switzerland market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Switzerland clinical trials market in every aspect of the classification from perspectives of Product Category, Phase, Design, Service Type, Indication, End User, and Region. Based on Product Category, the Switzerland market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. • Trials of Drugs o Small Molecule Drugs o Vaccines o Cell & Gene Therapy o Other Drugs • Trials of Devices • Trials of Procedures Based on Phase, the Switzerland market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. • Phase I • Phase II • Phase III • Phase IV By Design, the Switzerland market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. • Interventional Studies o Randomized Control Trial o Adaptive Clinical Trial o Non-randomized Control Trial • Observational Studies o Cohort Study o Case Control Study o Cross Sectional Study o Ecological Study • Expanded Access Trials By Service Type, the Switzerland market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. • Protocol Designing • Site Identification • Patient Recruitment • Laboratory Services • Bioanalytical Testing Services • Clinical Trial Data Management Services • Clinical Trial Supply & Logistic Services • Decentralized Clinical Trial Services • Medical Device Testing Services • Other Clinical Trial Services By Indication, the Switzerland market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. • Oncology • Infectious Diseases • Cardiology • Obesity • Diabetes • Neurology • Immunology • Pain Management • Other Indications By End User, the Switzerland market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. • Pharmaceutical and Biotechnological Companies • Clinical Research Organizations • Clinical Testing Laboratories • Other End Users Geographically, the following national/local markets are fully investigated: • Aargau [Argovia] • Appenzell Outer Rhodes • Appenzell Inner Rhodes • Basel-Landschaft • Basel-Stadt [Basel-City] • Bern • Fribourg • Genève [Geneva] • Glarus • Graubünden [Grisons] • Jura • Luzern • Neuchâtel • Nidwalden [Nidwald] • Obwalden [Obwald] • Schaffhausen • Schwyz • Solothurn • St. Gallen • Thurgau [Thurgovia] • Ticino • Uri • Valais • Vaud • Zug • Zürich [Zurich] For each key region, detailed analysis and data for annual revenue ($ mn) are available for 2022-2031. The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Accell Clinical Research LLC Charles River Laboratories ClinDatrix Inc Clinipace Eli Lilly and Company F. Hoffmann-La Roche Ltd. ICON PLC IQVIA Holdings, Inc. Laboratory Corporation of America (Covance Inc.) Novo Nordisk AS PAREXEL International Corporation Pfizer Inc. Pharmaceutical Product Development LLC PhlexSwitzerland PRA Health Sciences Sanofi SA SGS SA (SGS Life Sciences) Syneos Health Inc. Wuxi AppTec Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More